ArticleJACC. Case reports2022
Checkpoint Immunotherapy-Induced Myocarditis and Encephalitis Complicated With Complete AV Block: Not All Hope Is Lost.
Article in JACC. Case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review.International journal of molecular sciences · 2022Pooled it
- Immune checkpoint inhibitor-induced myocarditis with third-degree atrioventricular block: two case reports and literature review.Journal of geriatric cardiology : JGC · 2026Article
- Highly suspected fulminant myocarditis induced by the immune checkpoint inhibitor tislelizumab: a case report with third-degree atrioventricular block and recurrent ventricular tachycardia.Frontiers in cardiovascular medicine · 2026Article
- Myocarditis induced by a novel bifunctional PD-1/CTLA-4 combination antibody: a case report and literature review.BMC cardiovascular disorders · 2025Review
- Pacing therapy for immune checkpoint inhibitors-associated atrioventricular block: a single-center cohort study.BMC cardiovascular disorders · 2025Article
- Therapeutic agents for steroid-refractory immune checkpoint inhibitor-related myocarditis: a narrative review.Cardiovascular diagnosis and therapy · 2024Review
- Case Report: Temporary pacing using active fixation lead and invasive electrophysiology studies for immune checkpoint inhibitor associated reversible advanced atrioventricular block.Frontiers in cardiovascular medicine · 2024Article
- Occult checkpoint inhibitor myocarditis during adjuvant nivolumab plus ipilimumab: a smoldering but severe toxicity.Immunotherapy · 2024Article
- Multimodality imaging in cardio-oncology: the added value of CMR and CCTA.The British journal of radiology · 2023Review
- Immune Checkpoint Inhibitors-Related Myocarditis: A Review of Reported Clinical Cases.Diagnostics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors are associated with a myriad of autoimmune adverse events. We present a 70-year-old patient with renal-cell carcinoma treated with nivolumab/ipilimumab complicated with myocarditis and encephalitis in which gradual impairment of the His-Purkinje system progressed to complete atrioventricular block. Full recovery was achieved after treatment with corticosteroids and immunoglobulins. (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.